Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06223360 · ClinicalTrials.gov registry record · Phase 2

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

A Phase 2 study of Alzheimer Disease, sponsored by Alzheimer's Disease Cooperative Study (ADCS).

Recruiting
Registry status
Phase 2
Development phase
406
Enrollment target
20
Study locations

NCT06223360 is a Phase 2 study of Alzheimer Disease that is actively recruiting participants, run by Alzheimer's Disease Cooperative Study (ADCS). The registered enrollment target is 406 participants, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06223360, a Phase 2 study of Alzheimer Disease, is actively recruiting participants, sponsored by Alzheimer's Disease Cooperative Study (ADCS).

RECRUITING
Registry status
Phase 2
Development phase
406 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

Conditions Studied

Alzheimer Disease

Interventions

  • DRUG Placebo
  • DRUG Low Dose Benfotiamine
  • DRUG High Dose Benfotiamine

Study Locations (20)

Florida

  • JEM Research Institute - Atlantis
  • Brain Matters Research - Delray Beach
  • Neuropsychiatric Research Center of Southwest Florida - Fort Myers
  • CCM Clinical Research Group, LLC - Miami
  • Gonzalez MD & Aswad MD Health Services - Miami
  • Miami Jewish Health - Miami
  • Blue Medical Research Inc. - Miami
  • Brainstorm Research - Miami
  • Brain Matters Research (Kane Center) - Stuart
  • Conquest Research - Winter Park

California

  • The Neuron Clinic - Chula Vista
  • University of California, Irvine - Irvine
  • Pacific Research Network - Lemon Grove
  • University of Southern California - Los Angeles
  • Cedars Sinai, Los Angeles - Los Angeles
  • Syrentis Clinical Research - Santa Ana

Arizona

  • St. Joseph's Hospital and Medical Center/Barrow Neurological Institute - Phoenix
  • Perseverance Research Center, LLC - Scottsdale
  • Banner Sun Health Research Institute - Sun City

Georgia

  • Emory University Goizueta Alzheimer's Disease Research Center(GADRC) - Atlanta

Trial Details

FieldValue
Enrollment Target 406 participants
Start Date 2024-03-28
Est. Completion 2027-12-01
Phase Phase 2

Sponsor

Alzheimer's Disease Cooperative Study (ADCS)

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06223360

The ClinicalTrials.gov registry entry for NCT06223360 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,749-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (85% lower). The listed sponsor is Alzheimer's Disease Cooperative Study (ADCS), which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06223360 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT06223360 about?

NCT06223360 is a clinical study titled "A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)". The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.

What is the current status of trial NCT06223360?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2024-03-28. Estimated completion is 2027-12-01.

What conditions does trial NCT06223360 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT06223360?

The interventions under investigation include: Placebo (DRUG), Low Dose Benfotiamine (DRUG), High Dose Benfotiamine (DRUG).

Who is sponsoring clinical trial NCT06223360?

This trial is sponsored by Alzheimer's Disease Cooperative Study (ADCS), which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06223360 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.